Alcoholic Hepatitis - Pipeline Insight, 2025

This “Alcoholic Hepatitis - Pipeline Insight, 2025” report provides comprehensive insights about 11+ companies and 13+ pipeline drugs in Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Alcoholic Hepatitis: Understanding

Alcoholic Hepatitis: Overview

Alcoholic Hepatitis is an acute manifestation of alcoholic liver disease. The hepatic inflammation from the excess alcoholic intake often presents clinically as liver failure with jaundice, coagulopathy, and encephalopathy that can progress to multiorgan failure with high mortality. The use of corticosteroid as an anti-inflammatory agent in alcoholic hepatitis has proven useful in improving survival in a certain subset of patients with alcoholic hepatitis. Because the levels of inflammatory cytokines such as TNF-α are increased in alcoholic hepatitis, suppression may prove to be beneficial, especially in patients in whom corticosteroid use is contraindicated. Alcoholic hepatitis (AH) represents a significant public health burden.

Alcohol undergoes an oxidative metabolic pathway in the hepatocytes, leading to a reduced ratio of the nicotinamide adenine dinucleotide (NAD) to NADH. This promotes lipogenesis by inhibiting the oxidation of triglycerides and fatty acids. Another known mechanism of alcohol-induced liver injury is the translocation of endotoxins in the form of lipopolysaccharides (LPS), from the intestines into the hepatocytes. In the hepatic Kupffer cells, the LPS binds to CD 14 and toll-like receptor 4 to release a barrage of reactive oxygen species (ROS). The ROS activates the release of cytokines such as tumor necrosis factor-alpha (TNF alpha), interleukin-8, monocyte chemotactic protein 1 (MCP-1), and platelet-derived growth factor (PDGF), all of which leads to the accumulation of neutrophils, macrophages, and systemic clinical features of alcohol injury. Recent studies indicate that patients with specific intestinal dysbiosis have been increasingly susceptible to alcoholic liver disease and AH.

Alcoholic hepatitis typically develops over time with continued heavy drinking, but severe cases can emerge suddenly. This condition can rapidly progress to liver failure and even death if left untreated. Common symptoms of alcoholic hepatitis include belly tenderness or pain over the liver, nausea, vomiting blood or coffee-ground material, poor appetite, yellowing of the skin and eyes (jaundice), and weight loss.

There is no specific treatment for alcoholic liver disease at this time. Patients should be advised that continued alcohol use confers high risk of developing alcoholic hepatitis. Patients with acute severe alcoholic hepatitis are managed by active supportive therapy. Intake of at least 3,000 daily calories is associated with improved survival.

'Alcoholic Hepatitis - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alcoholic Hepatitis pipeline landscape is provided which includes the disease overview and Alcoholic Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Alcoholic Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alcoholic Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Alcoholic Hepatitis R&D. The therapies under development are focused on novel approaches to treat/improve Alcoholic Hepatitis.

Alcoholic Hepatitis Emerging Drugs Chapters

This segment of the Alcoholic Hepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alcoholic Hepatitis Emerging Drugs

INT-787: Intercept Pharmaceuticals

INT-787 is Intercept's next-generation farnesoid X receptor (FXR) agonist. Its characteristics provide an opportunity to explore its potential in diseases that involve the gut as well as the liver, such as severe alcohol-associated hepatitis (sAH). The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Alcoholic Hepatitis.

SRT-015: Seal Rock Therapeutics

SRT-015 is a second-generation ASK1 inhibitor with an improved safety profile. SRT-015 has been specifically designed for treating liver diseases. SRT-015 has a trimodal therapeutic mechanism with demonstrated direct antifibrotic, anti-inflammatory, and anti-apoptotic activities in vitro and in vivo. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Alcoholic Hepatitis.

Alcoholic Hepatitis: Therapeutic Assessment

This segment of the report provides insights about the different Alcoholic Hepatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Alcoholic Hepatitis

There are approx. 11+ key companies which are developing the therapies for Alcoholic Hepatitis. The companies which have their Alcoholic Hepatitis drug candidates in the most advanced stage, i.e. Phase II include, Intercept Pharmaceuticals.

Phases

The report covers around 13+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Alcoholic Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alcoholic Hepatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alcoholic Hepatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alcoholic Hepatitis drugs.

Alcoholic Hepatitis Report Insights

• Alcoholic Hepatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alcoholic Hepatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Alcoholic Hepatitis drugs?
• How many Alcoholic Hepatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alcoholic Hepatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alcoholic Hepatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alcoholic Hepatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Intercept Pharmaceuticals
• Seal Rock Therapeutics
• Surrozen
• Novartis Pharmaceuticals
• NEXEL
• Aldeyra Therapeutics

Key Products

• INT-787
• SRT-015
• SZN-043
• Canakinumab
• NP-011
• ADX-629

This product will be delivered within 2 business days.